Imugene Limited
Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA,… Read more
Market Cap & Net Worth: Imugene Limited (IUGNF)
Imugene Limited (PINK:IUGNF) has a market capitalization of $6.50 Million ($6.50 Million) as of March 19, 2026. Listed on the PINK stock exchange, this USA-based company holds position #31433 globally and #10348 in its home market, demonstrating a -35.48% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Imugene Limited's stock price $0.02 by its total outstanding shares 324760643 (324.76 Million).
Imugene Limited Market Cap History: 2019 to 2025
Imugene Limited's market capitalization history from 2019 to 2025. Data shows growth from $8.77 Million to $6.50 Million (27.26% CAGR).
Imugene Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Imugene Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.48x
Imugene Limited's market cap is 1.48 times its annual revenue
1740.90x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $8.77 Million | $4.13 Million | -$7.78 Million | 2.12x | N/A |
| 2020 | $26.96 Million | $4.13 Million | -$10.51 Million | 6.52x | N/A |
| 2021 | $96.29 Million | $7.23 Million | -$18.45 Million | 13.31x | N/A |
| 2022 | $35.37 Million | $12.97 Million | -$37.87 Million | 2.73x | N/A |
| 2023 | $19.49 Million | $11.78 Million | -$37.91 Million | 1.65x | N/A |
| 2024 | $7.86 Million | $4.97 Million | -$149.68 Million | 1.58x | N/A |
| 2025 | $6.50 Million | $4.40 Million | -$69.02 Million | 1.48x | N/A |
Competitor Companies of IUGNF by Market Capitalization
Companies near Imugene Limited in the global market cap rankings as of March 19, 2026.
Key companies related to Imugene Limited by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Imugene Limited Historical Marketcap From 2019 to 2025
Between 2019 and today, Imugene Limited's market cap moved from $8.77 Million to $ 6.50 Million, with a yearly change of 27.26%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $6.50 Million | -17.36% |
| 2024 | $7.86 Million | -59.67% |
| 2023 | $19.49 Million | -44.90% |
| 2022 | $35.37 Million | -63.27% |
| 2021 | $96.29 Million | +257.23% |
| 2020 | $26.96 Million | +207.41% |
| 2019 | $8.77 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of Imugene Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $6.50 Million USD |
| MoneyControl | $6.50 Million USD |
| MarketWatch | $6.50 Million USD |
| marketcap.company | $6.50 Million USD |
| Reuters | $6.50 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.